Gingko acquisition Zymergen’s problems were evident to board shortly after IPO, SEC filings show


Details of Zymergen's rise and fall emerged in a document filed Friday by Boston-based Gingko Bioworks, which is in the process of acquiring the California biotech in an all-stock deal valued at $300 million.

Previous United Arab Emirates-based company buys $500M stake in Nashville's Ardent Health
Next AstraZeneca receives expanded FDA approval for multibillion-dollar cancer treatment